Recipharm
Recipharm AB, a leading contract development and manufacturing organisation (CDMO), is headquartered in Sweden (SE) and operates extensively across Europe, North America, and Asia. Founded in 1995, Recipharm has established itself as a key player in the pharmaceutical industry, specialising in the development and production of complex drug formulations, including sterile and non-sterile products. The company offers a diverse range of services, from drug development and manufacturing to packaging and analytical services, catering to both small biotech firms and large pharmaceutical companies. Recipharm's commitment to quality and innovation has earned it a strong market position, with notable achievements in expanding its global footprint and enhancing its technological capabilities. With a focus on sustainability and efficiency, Recipharm continues to set benchmarks in the CDMO sector, making it a trusted partner for pharmaceutical companies worldwide.
DitchCarbon Score
How does Recipharm's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Recipharm's score of 39 is higher than 98% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Recipharm's reported carbon emissions
In 2023, Recipharm reported total carbon emissions of approximately 65466000 kg CO2e, comprising 65466000 kg CO2e from Scope 1 and 4466000 kg CO2e from Scope 2 emissions. The company also disclosed significant Scope 3 emissions, amounting to about 515791000 kg CO2e. This represents a notable increase in emissions compared to previous years, highlighting the challenges faced in reducing their carbon footprint. Recipharm has set ambitious climate commitments, aiming for Net Zero emissions across all scopes by 2050. Specifically, they target Net Zero Scope 2 emissions by 2030 and Scope 1 emissions by 2040. In the near term, the company has committed to reducing absolute Scope 1 and 2 GHG emissions by 42.1% by 2030 from a 2021 baseline. Additionally, they aim to increase their sourcing of renewable electricity from 93.5% in 2021 to 100% by 2030. For Scope 3 emissions, Recipharm plans to achieve a 25% reduction within the same timeframe. These initiatives align with industry standards for climate action, reflecting Recipharm's commitment to sustainability and reducing their environmental impact in the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 12,442,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 17,517,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | 463,000 | 000,000 | 000,000 | 000,000 | 0,000,000 | 000,000 | 00,000 | - | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Recipharm is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
